1. Home
  2. ARQT vs MSDL Comparison

ARQT vs MSDL Comparison

Compare ARQT & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • MSDL
  • Stock Information
  • Founded
  • ARQT 2016
  • MSDL 2019
  • Country
  • ARQT United States
  • MSDL United States
  • Employees
  • ARQT N/A
  • MSDL N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • MSDL
  • Sector
  • ARQT Health Care
  • MSDL
  • Exchange
  • ARQT Nasdaq
  • MSDL NYSE
  • Market Cap
  • ARQT 1.7B
  • MSDL 1.7B
  • IPO Year
  • ARQT 2020
  • MSDL N/A
  • Fundamental
  • Price
  • ARQT $15.00
  • MSDL $19.25
  • Analyst Decision
  • ARQT Strong Buy
  • MSDL Hold
  • Analyst Count
  • ARQT 6
  • MSDL 5
  • Target Price
  • ARQT $18.80
  • MSDL $20.00
  • AVG Volume (30 Days)
  • ARQT 2.0M
  • MSDL 431.0K
  • Earning Date
  • ARQT 08-13-2025
  • MSDL 01-01-0001
  • Dividend Yield
  • ARQT N/A
  • MSDL 11.43%
  • EPS Growth
  • ARQT N/A
  • MSDL N/A
  • EPS
  • ARQT N/A
  • MSDL N/A
  • Revenue
  • ARQT $212,819,000.00
  • MSDL N/A
  • Revenue This Year
  • ARQT $61.15
  • MSDL $1,597.39
  • Revenue Next Year
  • ARQT $37.98
  • MSDL $15.10
  • P/E Ratio
  • ARQT N/A
  • MSDL N/A
  • Revenue Growth
  • ARQT 100.03
  • MSDL N/A
  • 52 Week Low
  • ARQT $7.86
  • MSDL $17.59
  • 52 Week High
  • ARQT $17.75
  • MSDL $23.63
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 60.23
  • MSDL 50.38
  • Support Level
  • ARQT $13.06
  • MSDL $18.84
  • Resistance Level
  • ARQT $15.36
  • MSDL $19.19
  • Average True Range (ATR)
  • ARQT 0.66
  • MSDL 0.28
  • MACD
  • ARQT 0.12
  • MSDL 0.02
  • Stochastic Oscillator
  • ARQT 82.57
  • MSDL 75.95

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

Share on Social Networks: